IL321364A - A kit for use in the treatment of hematological cancer - Google Patents

A kit for use in the treatment of hematological cancer

Info

Publication number
IL321364A
IL321364A IL321364A IL32136425A IL321364A IL 321364 A IL321364 A IL 321364A IL 321364 A IL321364 A IL 321364A IL 32136425 A IL32136425 A IL 32136425A IL 321364 A IL321364 A IL 321364A
Authority
IL
Israel
Prior art keywords
kit
treatment
hematological cancer
hematological
cancer
Prior art date
Application number
IL321364A
Other languages
Hebrew (he)
Original Assignee
Avencell Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP22212572.6A external-priority patent/EP4382119A1/en
Application filed by Avencell Europe Gmbh filed Critical Avencell Europe Gmbh
Publication of IL321364A publication Critical patent/IL321364A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL321364A 2022-12-09 2023-12-07 A kit for use in the treatment of hematological cancer IL321364A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22212572.6A EP4382119A1 (en) 2022-12-09 2022-12-09 A kit for use in the treatment of hematological cancer
EP23207275 2023-11-01
PCT/EP2023/084689 WO2024121297A1 (en) 2022-12-09 2023-12-07 A kit for use in the treatment of hematological cancer

Publications (1)

Publication Number Publication Date
IL321364A true IL321364A (en) 2025-08-01

Family

ID=89158176

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321364A IL321364A (en) 2022-12-09 2023-12-07 A kit for use in the treatment of hematological cancer

Country Status (7)

Country Link
EP (1) EP4630041A1 (en)
JP (1) JP2025540251A (en)
KR (1) KR20250111218A (en)
CN (1) CN120882422A (en)
AU (1) AU2023389158A1 (en)
IL (1) IL321364A (en)
WO (1) WO2024121297A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders

Also Published As

Publication number Publication date
WO2024121297A1 (en) 2024-06-13
AU2023389158A1 (en) 2025-06-05
JP2025540251A (en) 2025-12-11
EP4630041A1 (en) 2025-10-15
CN120882422A (en) 2025-10-31
KR20250111218A (en) 2025-07-22

Similar Documents

Publication Publication Date Title
IL290415A (en) Deuterated compounds for use in the treatment of cancer
EP4066837A4 (en) Use of bi853520 in cancer treatment
IL320302A (en) Combinations of a serd for the treatment of cancer
LT4340842T (en) Sotorasib for use in the treatment of cancer
EP4129206C0 (en) Surgical kit
IL284856A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer
IL292143A (en) Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
IL317116A (en) Chelating agents for use in cancer therapy
IL321364A (en) A kit for use in the treatment of hematological cancer
IL314316A (en) Compounds and their use in treating cancer
IL179129A0 (en) Kit for treatment of cancer
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
CA3274543A1 (en) A kit for use in the treatment of hematological cancer
IL306046A (en) A composition for use in treating mhc-1-opathies
PL4146225T3 (en) Methylthioninium compounds for use in the treatment of hypoxemia
GB202019316D0 (en) A bone reduction kit
GB202301081D0 (en) Catheter kit
GB202209124D0 (en) Novel composition having use in therapy
ZA202212090B (en) Peptides containing a pcna interacting motif for use in the treatment of solid cancer
GB202209316D0 (en) Novel compositions having a use in therapy
GB202305026D0 (en) Novel compositions having use in therapy
GB202110150D0 (en) Compounds useful in therapy
HK40129002A (en) Combination for use in treating cancers
CA3269114A1 (en) Combination for use in treating cancers
IL316821A (en) Cancer treatment with nuc-7738